CTLA4 and head and neck squamous cell carcinoma: The relatively low major pathological response rate after neoadjuvant dual ICB with anti-PD-1 and anti-CTLA-4 of 20–35% in HNSCC, however, underlines the need to select of patients likely to respond [6, 7].